Record revenue, margin squeeze, solid execution on growth roadmap
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
No prior numeric guidance on record. Acknowledged RM cost impact and expected margin hold H2 vs H1—both corroborated by delivered result.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Sedemac delivered record quarterly revenue (₹400.6 Cr) with 29% QoQ growth and confirmed strong momentum on ISG+EFI (1M+ deployments) and new platforms (power tools, commercial vehicles). However, OPM compressed to 18.9% from RM cost inflation despite acknowledged operating leverage, signaling near-term earnings headwinds. Long-term thesis is solid (38% 3yr CAGR, multiple new markets), but power tools market is early-stage and competitive, and Q2 may represent peak quarterly revenue before new plant ramp absorbs capex.
₹400.6 Cr
Revenue · +null% YoY₹39.2 Cr
Reported PAT · +null% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 & H1 highest revenue ever with 40%+ growth
MET400.6 Cr revenue (confirmed highest quarterly), 29.3% QoQ. YoY growth rate unverified.
EBITDA margin dip due to raw material cost surge
METOPM 18.9%, NPM 9.8%, indicating margin compression. RM cost pressure acknowledged.
Operating leverage offsetting RM cost increases despite 40%+ growth
METDelivered 29.3% QoQ revenue growth with margin dip, consistent with claim.
ISG+EFI shipped >1M units in last 8 months with full ramp
UnverifiedNo independent verification in delivered result, but call stated near ~500K TTM run rate ramping.
Earnings quality
What changed since the last call
ISG+EFI production milestone updated
Upgrade>1M units shipped in last 8 months (vs prior call narrative of ramp). Demonstrates market traction and supply chain readiness.
Commercial vehicle market entry formalized
NewAfter-treatment controller, EFI ECUs, MCUs for commercial vehicles entering production next few quarters. Opens new TAM.
Power tools market win announced
NewMagneto Kit from European 2/3-wheeler OEM; production H1 FY28. Early entry into large, nascent market.
Plant expansion accelerated
UpgradeMF5 land acquired in Shoolagiri, Tamil Nadu (larger than MF3). MF3 now in pilot production ahead of schedule.
Capex guidance reset higher
NeutralCapex 227 Cr (FY26) → 450 Cr (H1FY27). H2 expected lower, but cumulative capex cycle will deleverage near-term.
The Q&A
Analysts pressed on RM cost pass-through (no automatic indexation), working capital build, power tools market timing, ISG/EFI competitive risk, and capex H2. Management was transparent on pricing mechanics and acknowledged margin headwinds but held firm on long-term growth drivers.
RM cost, pricing mechanics — Kale Nikhil, undefined
AnsweredNo automatic pass-through. Pricing negotiated. Insulated for forex via formulas; RM increases subject to ongoing negotiation with customers.
Chip supplier dependency — Venkata Siva Ram Chodapaneedi, undefined
AnsweredNo single-chip dependency. Multiple suppliers, non-obvious fallbacks post-COVID. India sourcing limited today, monitoring.
ISG vs ISG+EFI value prop — Vipul Agrawal, undefined
AnsweredEFI ECU mandatory for emissions. Sedemac proven (>1M deployments). Key hurdle: OEM relationships with incumbent EFI suppliers; Sedemac differentiates on flexibility.
Power tools market timeline — Shashikanth Suryanarayanan (MD), to Vijay Bhatia
PartialEarly stage of engagement with strong interest from top players. Magneto Kit win with European OEM, production H1 FY28. Sensor-less commutation is meaningful. Similar trajectory to ISG 2017-18 inflection.
Capex H2 outlook — Prasad Hase, undefined
PartialWon't give exact number, but H2 lower than H1 as MF3 nearing completion. No H2 FY28 detail provided.
Working capital trend — Kale Nikhil, undefined
AnsweredWC not substantially increased as % of revenue. Mainly driven by 400 Cr Q2 revenue base. Pressure but linked to growth, not external stress.
R&D pipeline visibility — Sahil Jain, undefined
DodgedCannot share detail due to competitive risk. Track record has been good on yielding propositions. New product launches happening in coming quarters.
CV product launch delay — Prasad Hase, undefined
PartialNormal OEM program timeline shifts. Extremely natural; no big deal. Part of regular program cadence.
Patent strategy & IP — Ayush Jhunjhunwala, undefined
AnsweredCore patent technology is never-ending; file new patents for adjacent products as market demands. Patents are about technology, not markets.
Sensor-less MCU competitive risk — Sakshat, undefined
AnsweredAlready selling MCUs, E2/3 penetration in line with EV adoption (11.4% in H1). Engaged with OEMs on adoption; no inflection risk.
Guidance
No quantified FY27 target; growth momentum at 40%+ continues
MediumH1 YoY growth not disclosed. Q2 ₹400.6 Cr described as highest ever; new launches to sustain growth.
EBITDA expected to hold H2 vs H1FY27 despite ongoing RM cost pressure
MediumPredicated on price negotiations with customers and operating leverage from continued growth offsetting RM inflation.
H2 FY27 capex will be lower than H1; H2 FY27/FY28 full amount not quantified
MediumH1 capex ~₹450 Cr (pro-rata annualized). MF3 nearing completion, reducing capex intensity in H2.
Risks the call surfaced
RM cost pressure
HighRM inflation unabated; pricing negotiated with customers, not indexed. Capex cycle absorbs internal accruals.
Power tools market
MediumPower tools market entry is early-stage. Magneto Kit production H1 FY28. Competitive positioning vs incumbent motor control suppliers unclear; large global tier-ones already present.
EV 2/3-wheeler penetration
LowISG+EFI relevance hinges on EV 2/3-wheeler growth. Penetration only 11.4% in H1 FY27. If electrification pace slows, demand for EVcentric products weakens.
Capex execution risk
MediumMF3 plant ramp and MF5 new facility acquisition; capex jumped 227→450 Cr. Execution delays or cost overruns could stress cash flow.
Customer concentration
MediumTop customer revenue declining as Sedemac wins new OEM customers. Concentration metric improved but still meaningful. New launches (power tools, commercial vehicles) will further diversify.
Management
Score 8/10. Clear on operational metrics and product roadmap. Candid on RM cost headwinds and margin pressure. Transparent on power tools market early-stage risk. Deflected on R&D pipeline (competitive concerns). Track record strong: ISG+EFI >1M units in 8 months, E2MCU fully ramped, MF3 pilot started on schedule. No prior guidance misses documented; guided conservatively on capex H2.
1 · Q3 FY27 (Oct-Dec)
MF3 full production ramp; after-treatment controller & EFI ECU commercial vehicle launch
2 · H1 FY28 (Apr-Jun)
Magneto Kit production ramp with European 2/3-wheeler OEM
3 · FY28 (Apr-Mar)
MF5 plant operational in Tamil Nadu; drive revenue base to 2x+ current level
Long-term thesis is solid (38% 3yr CAGR, multiple new markets), but power tools market is early-stage and competitive, and Q2 may represent peak quarterly revenue before new plant ramp absorbs capex.
Record Revenue, Margin Reality Check
Sedemac delivered its highest-ever revenue (₹400.6 Cr, +29% QoQ) on strong momentum, but operating profit margin compressed to 18.9% as raw material inflation outpaced pricing power. The core question: Is this a temporary cost headwind, or a structural drag on near-term earnings?
₹400.6 Cr
Highest ever, +29% QoQ
18.9%
Compressed from RM costs
₹39.2 Cr
+18% QoQ (lag vs revenue growth)
On paper, a blowout quarter: revenue hit an all-time high of ₹400.6 crore—a 29% quarter-on-quarter surge. But here's the tension: profit growth (18% QoQ) significantly lagged revenue growth (29% QoQ), the telltale signature of margin compression. Operating margin fell to 18.9%, a noticeable dip that management attributed to raw material inflation. The critical question: Is this a temporary cost headwind that will ease as capex moderates and pricing negotiations catch up, or a structural pressure on near-term earnings that will persist?
The operating leverage claim: what holds up
Operating leverage from 40%+ revenue growth is offsetting RM cost increases
Revenue grew 29% QoQ; PAT grew 18% QoQ. OPM fell to 18.9% despite strong absolute revenue. Operating leverage exists but is not offsetting the full RM cost impact.
Partially supported
RM cost inflation impact is 'bit of a dip', not structural
OPM compressed visibly in Q2; management stated RM costs remain elevated. Pricing is negotiated case-by-case, not indexed—no automatic pass-through.
Supported (but not a one-off)
EBITDA will hold H2 vs H1FY27 despite ongoing RM pressure
No H1/H2 breakdown provided in Q2 result. Management guided conservatively on H2 capex being lower, which would help stabilize margins if volumes hold.
Credible but unverified
Where the margin went
Revenue jumped 29% QoQ but PAT rose only 18%, signaling an earnings shortfall of roughly 11 percentage points. Two forces are at work. First: RM cost inflation absorbed by Sedemac rather than passed to customers. Pricing is negotiated on a case-by-case basis, not indexed to commodity prices—a structural disadvantage when material costs spike. Second: Heavy capex spending. Capex surged from ₹227 crore (FY26 full year) to roughly ₹450 crore annualized in H1 FY27, a near-doubling. MF3 plant startup and MF5 land acquisition in Tamil Nadu are consuming cash faster than revenue growth offsets. The mitigating factor: Management guided H2 capex to be "lower than H1," suggesting H2 could see some margin relief as capex moderates relative to revenue.
What changed on this call
ISG+EFI ramp accelerating: >1 million units shipped in last 8 months (faster than prior-quarter narrative)
Commercial vehicle market entry formalized: After-treatment controllers, EFI ECUs, and MCUs entering production next few quarters
Power tools market win: Magneto Kit for European 2/3-wheeler OEM; production ramp expected H1 FY28
Plant expansion accelerated: MF5 land acquired in Shoolagiri, Tamil Nadu; MF3 pilot production started ahead of schedule
Capex cycle strains near-term FCF: H1 run-rate ~₹450 Cr annualized; deleveraging will persist until capex moderates
The bull-bear ledger
Highest-ever quarterly revenue; 40%+ recent growth momentum sustained from prior year
ISG+EFI milestone (>1M units) validates market adoption and supply chain readiness
Three new platforms ramping: commercial vehicles, power tools, sensor-less MCUs—meaningful TAM diversification
Management track record solid: No prior guidance misses; delivered on product roadmap and capacity milestones
Margin compression is real; RM cost not fully passed through to customers—near-term earnings headwind
Capex cycle is heavy: H1 run-rate ~₹450 Cr on ₹400 Cr quarterly revenue (capex intensity >100% of Q2 revenue)
Power tools market entry is early-stage and competitive; management candid: 'Nobody knows if we will succeed'
EV 2/3-wheeler penetration only 11.4%—core growth thesis hinges on electrification pace, not yet structural
Ranked risks: what should concern a holder
Raw material cost pressure unabated; pricing negotiated, not indexed
HighOPM fell to 18.9% despite 29% revenue growth. If commodity prices stay elevated and customers resist further price hikes, margin dip persists into H2 and FY28. This is the key near-term earnings drag.
Capex cycle delevering near-term free cash flow
HighCapex ~₹450 Cr annualized vs. ₹227 Cr prior year full year. MF3 and MF5 ramps will absorb cash. Deleveraging and shareholder capital return capacity limited until capex moderates in H2 FY28+.
Power tools market entry is early-stage and highly competitive
MediumManagement acknowledged real uncertainty ('Nobody knows if we will succeed'). Bosch, Denso, Infineon already dominant in motor control. Sedemac's advantage (sensor-less tech) is real but volumes and margins are unproven.
EV 2/3-wheeler penetration still niche (11.4% of market in H1)
MediumCore thesis hinges on electrification pace. If EV adoption slows or plateaus below forecasts (vehicle-price sensitive market), demand for EV-centric products weakens and ISG+EFI ramp stalls.
Capex execution and cost overrun risk on MF3/MF5
MediumMF3 and MF5 ramps depend on flawless execution. Delays or cost overruns would strain FCF further and push deleveraging timeline out by 1-2 years.
How the street is reading it
The stock is trading at ₹3093, down 14.27% from its all-time high of ₹3607.8 but still +118.88% above its 52-week low. It's currently trading below its 20-day and 50-day moving averages, signaling near-term technical weakness. The RSI is neutral at 46.9, suggesting no extreme overbought or oversold condition. On the surface, this repricing seems harsh for a record revenue print—but the market is rational to be cautious. Margin compression and heavy capex spending are dimming near-term EPS visibility, even if long-term growth drivers remain intact.
Institutional flows reveal a mixed stance. FII ownership rose 1.75 percentage points to 4.27% in Q1 FY27, a modest positive signal. However, bulk and block deals in the ₹3010 price range tell the real story: A91 Emerging Fund (a growth specialist) sold 16.1 million shares; Xponentia Opportunities Fund sold 9.9 million shares; HDFC Life trimmed positions multiple times. On the flip side, T Rowe Price, Invesco, Franklin Templeton, and the Monetary Authority of Singapore bought. The pattern: global value and sovereign wealth are nibbling on the dip, while domestic growth-focused funds are trimming. This classic divergence signals caution among growth investors and selective bargain-hunting by value investors—a sign that the margin headwind and capex cycle are genuine concerns, not just near-term noise.
The debate
1 · Q3 FY27: Margin stabilization signal
Management guided EBITDA to hold H2 vs H1FY27. If OPM stays at 18-19% in Q3 and RM cost inflation doesn't worsen, the bear case weakens and capex cycle becomes manageable. If OPM dips below 18%, the margin headwind is structural and more severe than guided.
2 · Commercial vehicle & power tools production ramp
Commercial vehicle launches (after-treatment controller, EFI ECU) and Magneto Kit production both guided for H1 FY28 ramp. If these platforms ship material volumes (>10-15% of quarterly revenue by Q4 FY27), diversification thesis gains traction and reduces ISG+EFI concentration risk. Delays would signal execution risk.
3 · H2 FY27 capex execution vs. guidance
Management said H2 capex will be "lower than H1." If H2 comes in <₹200 Cr and FCF turns positive (vs. consumed by capex), the cash flow cycle stabilizes. Beats to capex guidance would unlock near-term shareholder return capacity.
Sedemac is not broken—record revenue and ISG+EFI milestone (>1M units) prove genuine market momentum. But Q2 is a yellow flag on near-term earnings. Margin compression, capex absorption, and early-stage new markets (power tools, commercial vehicles) mean the stock has shifted from pure-growth story to 'execution matters' story. The market has already repriced it 14% off the high; the reset is partially justified.
Verdict: Hold on a 'show me' basis. The number to track from here is operating margin in H2 FY27. If OPM holds at 18-19%, the bull thesis survives. If it dips below 18%, the margin problem is structural and downside risk rises. Either way, clarity arrives in 3-4 months.
Sedemac Q2 FY27: standalone PAT +30% YoY to ₹39 Cr, revenue +40%, but margins slip
PAT +30% YoY · revenue +39.85% · margins compressing
₹400.64 Cr
+39.85% YoY
₹39.18 Cr
+30% YoY
9.76%
₹8.87
Sedemac Mechatronics reported standalone revenue of ₹400.64 Cr (+39.9% YoY, +29.3% QoQ) and PAT of ₹39.18 Cr (+30.0% YoY, +17.6% QoQ) for Q2 FY27, with EPS at ₹8.87 versus ₹7.06 a year ago. Growth was driven almost entirely by the Mobility segment, up 52.6% YoY to ₹366.35 Cr on record quarterly ECU shipments of 1.45 million units (+37.5% YoY, per company disclosure), while the smaller Industrial segment slipped to ₹34.29 Cr from ₹46.46 Cr.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
Profitability growth trailed revenue growth: net profit margin contracted to 9.78% from 10.52% a year ago (and from 10.72% last quarter), while operating margin eased to 18.86% from 21.32% YoY. The squeeze sits on finance costs, which more than doubled YoY to ₹5.87 Cr, and depreciation, up 34% YoY to ₹19.78 Cr — both tied to the new Pune manufacturing facility that began commercial production on 25 September 2026; right-of-use assets jumped to ₹144.16 Cr from ₹19.95 Cr at FY26-end as the company added lease-funded capacity. Segment profitability diverged sharply: Mobility PBT grew 28.1% YoY to ₹49.42 Cr while Industrial PBT fell 33.9% to ₹5.19 Cr.
The stock went into the print at ₹3,212, down 7.4% over the past month of trading.
What the summary numbers don't show
Borrowings (current + non-current) rose to ₹245.64 Cr from ₹50.63 Cr at FY26-end — H1 FY27 operating cash flow was negative ₹20.38 Cr on inventory (+53% to ₹287.81 Cr) and receivables build; cash fell to ₹0.70 Cr
The company has issued no formal guidance on record, and no quarter-specific Street consensus for Q2 FY27 revenue or PAT could be located, so the print cannot be scored against a published estimate. Public full-year FY27 revenue consensus sits near ₹1,490 Cr; against that, H1 FY27 revenue of ₹710.41 Cr implies roughly ₹780 Cr is needed in H2, plausible given the new capacity ramp. This quarter's other disclosed developments — SBI Mutual Fund's 5.26% stake purchase and the 82,400 ESOP grant — have no direct P&L tie-in beyond equity-settled share-based payments of ₹0.90 Cr for H1; the filing carries no separate management commentary or press release to cross-check against the numbers.
W1
Whether OPM/NPM stabilize as the new Pune facility moves past initial depreciation/finance-cost drag (OPM 18.86% this quarter vs 21.32% a year ago)
W2
Industrial segment recovery — PBT down 33.9% YoY to ₹5.19 Cr this quarter
W3
Working-capital and cash trajectory after a negative ₹20.38 Cr H1 FY27 operating cash flow and inventory build to ₹287.81 Cr
Company has no subsidiary/associate/JV (note 5) so only a standalone statement exists; no exceptional items this quarter (Q1 FY27's ₹2.98 Cr tax-reversal one-off does not apply here); limited-review (unaudited), unqualified conclusion.